OpenScience.ink

4 days ago • Metabolism: clinical and experimental

How Metabolism-Related Signals and Obesity Treatments Are Linked to Brain Changes and Nerve Cell LossThe metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration.

🥈 Top 2% JournalArticle

4 days ago • Exploratory research in clinical and social pharmacy

How pharmacists help people stick to GLP-1 weight loss medicines by managing side effectsThe pharmacist's role in enhancing adherence to GLP1 based anti-obesity medications through comprehensive side effect management.

📖 Top 50% JournalArticle

4 days ago • The Journal of physiology

Time-restricted eating and strength training improve tirzepatide's effects on body fat and insulin sensitivity in female miceCombined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice.

🎖️ Top 10% JournalArticle

4 days ago • Alzheimer's & dementia (New York, N. Y.)

Combined buntanetap and dulaglutide reduce brain cell communication problems and memory loss in a mouse model of Alzheimer's diseaseCombined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.

🥉 Top 5% JournalArticle

4 days ago • Expert review of clinical pharmacology

Using Diabetes Drugs Targeting GLP-1 Receptors as Possible Treatment for Substance Use DisordersFrom metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders.

📖 Top 20% JournalArticle

4 days ago • Med (New York, N.Y.)

Using Metabolic Profiles to Guide Alzheimer's and Parkinson's Disease Trials Based on Disease MechanismsMetabolic endotyping for mechanism-informed Alzheimer's and Parkinson's disease trials.

🥈 Top 2% JournalArticle

4 days ago • Journal of the American Heart Association

Effects of Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure Patients with Normal Heart PumpingGlucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.

🥉 Top 5% JournalArticle

5 days ago • Journal of vascular surgery

GLP-1 Receptor Agonists May Lower Rupture Risk, Heart Problems, and Death in Patients with Abdominal Aortic AneurysmsGLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.

🥉 Top 5% JournalArticle

5 days ago • Journal of the neurological sciences

Glucagon-like peptide-1 as a recovery marker after brain injury in people with obesity: Early findingsGlucagon-like peptide-1 as a recovery biomarker after traumatic brain injury in patients with obesity: Preliminary results.

📖 Top 20% JournalArticle

5 days ago • American journal of kidney diseases : the official journal of the National Kidney Foundation

Key Links Between Kidney and Digestive System DisordersThe Crossroads Between the Kidney and Gastrointestinal Disorders: Core Curriculum 2026.

🥉 Top 5% JournalArticle

5 days ago • Diabetes research and clinical practice

Semaglutide compared to other similar diabetes drugs and heart risk in cancer survivors with obesitySemaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors.

🎖️ Top 10% JournalArticle

6 days ago • The Journal of clinical endocrinology and metabolism

Normal-Weight Fatty Liver Disease Linked to Higher Risk of Death, Heart Problems, Cancer, and Less Use of GLP-1 MedicationNormal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.

🥉 Top 5% JournalArticle

6 days ago • Medical care research and review : MCRR

Use of Glucagon-Like Peptide-1 Drugs Among Medicaid Patients: Findings From Policy and Prescription DataGlucagon-Like Peptide-1 Receptor Agonists and Medicaid: Insights From Policy and Prescription Data.

🎖️ Top 10% JournalArticle

6 days ago • Molecular metabolism

Ongoing CagriSema treatment keeps weight off by lowering food intake and keeping energy use steady in ratsContinued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.

🥉 Top 5% JournalArticle

6 days ago • Journal of diabetes science and technology

Multiple Health Effects of GLP-1 Receptor Agonists Compared to Other Treatments in Type 2 DiabetesMultisystem Outcomes of GLP-1 Receptor Agonists Versus Active Comparators in Type 2 Diabetes: A Multicenter Target Trial Emulation.

🎖️ Top 10% JournalArticle

1 week ago • Neuropharmacology

Semaglutide lowers alcohol drinking and anxiety-like behavior during withdrawal in alcohol-preferring ratsThe GLP-1 receptor agonist semaglutide reduces alcohol consumption and anxiety-like behaviors during withdrawal in Marchigian Sardinian alcohol-preferring rats.

🎖️ Top 10% JournalArticle

1 week ago • JAMA network open

Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Type 2 Diabetes: Updated Guidelines and Changes in Doctors' Knowledge Over TimePrescribing SGLTis and GLP-1 RAs for Patients With Type 2 Diabetes, Guideline Updates, and Longitudinal Knowledge Assessment Scores.

🥈 Top 2% JournalArticle

1 week ago • Clinical and molecular hepatology

GLP-1 receptor drugs and health risks in people with type 2 diabetes and long-term viral liver infectionGLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepatitis.

🥈 Top 2% JournalArticle

1 week ago • JAMA network open

Recording and Coding Body Mass Index in Medicare Patients Receiving Obesity TreatmentBody Mass Index Documentation and Coding Among Medicare Beneficiaries Undergoing Obesity Treatment.

🥈 Top 2% JournalArticle

1 week ago • Journal of the American Chemical Society

Using Mass Spectrometry to Reveal How Semaglutide Molecules Change Shape and Group TogetherStructural Mass Spectrometry Resolves the Conformational Dynamics of Semaglutide Oligomerization.

🥇 Top 1% JournalArticle

1 week ago • JAMA network open

Prescribing GLP-1 Receptor Agonists for People with Type 2 Diabetes and CancerGLP-1 RA Prescribing in Patients With Type 2 Diabetes and Cancer.

🥈 Top 2% JournalArticle

1 week ago • Current opinion in clinical nutrition and metabolic care

Glucagon-like peptide-1 drugs for treating obesity in older adults: possible risks and benefitsThe use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.

📖 Top 20% JournalArticle

1 week ago • JDR clinical and translational research

Mouth and Dental Side Effects of GLP-1 Receptor Agonist MedicationsOral Health-Related Adverse Events of GLP-1 Receptor Agonists.

📖 Top 20% JournalArticle

1 week ago • Diabetes research and clinical practice

Thyroid monitoring during GLP-1 receptor agonist treatment and its possible link to thyroid cancer detectionThyroid surveillance practices in GLP-1 receptor agonist use and its potential influence on thyroid cancer detection: A scoping review.

🎖️ Top 10% JournalArticle

1 week ago • Kidney medicine

Risk of Diabetic Eye Disease in People with Moderate to Severe Kidney Disease and Type 2 Diabetes Starting SGLT2 Inhibitors Versus GLP-1 Receptor AgonistsDiabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes.

📖 Top 20% JournalArticle

1 week ago • Obesity pillars

Orforglipron's safety and effectiveness in adults with mild overweight and fat-related health problemsEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.

📖 Top 20% JournalArticle

1 week ago • Clinical pharmacology and therapeutics

Use of Three Diabetes Medicines and New Low Sodium Levels in Patients with Type 2 DiabetesUse of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations.

🥉 Top 5% JournalArticle

1 week ago • Aesthetic plastic surgery

Comparing Results of Tummy Tuck Surgery After Large Weight LossA Comparative Outcome Review of Abdominoplasty Following Massive Weight Loss.

📖 Top 20% JournalArticle

1 week ago • Maturitas

Incretin-based treatments for women during menopause: Current overviewIncretin-based therapies in menopause: Current landscape.

📖 Top 20% JournalArticle

1 week ago • Advances in therapy

Skeletal Muscle and Its Response to Heart, Kidney, and Metabolism Treatments in Vulnerable Patients: SGLT2 Inhibitors, Incretin-Based Drugs, and Challenges in Personalized CareSkeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.

📖 Top 20% JournalArticle

← prevpage 6 of 16next →

GLP-1 Therapies Research Papers